Zoetis Inc.

Equities

ZTS

US98978V1035

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-09-13 pm EDT 5-day change 1st Jan Change
191.09 USD +0.20% Intraday chart for Zoetis Inc. +0.98% -3.18%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : Zoetis Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:05 PM
Piper Sandler Adjusts Price Target on Zoetis to $210 From $195 MT
BTIG Adjusts Price Target on Zoetis to $225 From $220, Maintains Buy Rating MT
Jefferies Adjusts Price Target on Zoetis to $210 From $200 MT
Redburn Atlantic Adjusts Price Target on Zoetis to $225 From $220 MT
Barclays Adjusts Price Target on Zoetis to $242 From $230 MT
Tranche Update on Zoetis Inc.'s Equity Buyback Plan announced on December 7, 2021. CI
Global markets live: Bayer, GSK, Boeing, Lucid, Palantir... Our Logo
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday MT
Sector Update: Health Care MT
Transcript : Zoetis Inc., Q2 2024 Earnings Call, Aug 06, 2024
Zoetis Q2 Adjusted Earnings, Revenue Rise; 2024 Outlook Lifted MT
Zoetis Raises Guidance After 2Q Sales, Earnings Rise DJ
Stocks Rebound Pre-Bell as Investors Digest Global Selloff, Await Earnings; Europe, Asia Mixed MT
(ZTS) ZOETIS Forecasts Fiscal Year 2024 Revenue Range $9.1B - $9.25B MT
(ZTS) ZOETIS Expects Fiscal Year 2024 Adjusted EPS Range $5.78 - $5.88 MT
Earnings Flash (ZTS) ZOETIS Posts Q2 Revenue $2.36B MT
Earnings Flash (ZTS) ZOETIS Posts Q2 Adjusted EPS $1.56 MT
Zoetis Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Zoetis Inc. Raises Earnings Guidance for the Year 2024 CI
Stifel Nicolaus Adjusts Zoetis Price Target to $200 From $180 MT
Zoetis Authorizes $6 Billion Stock Buyback Program MT
Zoetis Inc. announces an Equity Buyback for $6,000 million worth of its shares. CI
Zoetis Inc. authorizes a Buyback Plan. CI
BTIG Initiates Zoetis With Buy Rating, $220 Price Target MT
Chart Zoetis Inc.
More charts
Logo Zoetis Inc.
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%); - livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%); - other (1.1%). Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%). At the end of 2022, the group has 29 production sites worldwide. The United States accounts for 53.4% of net sales.
Employees
14,100
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
191.09USD
Average target price
213.12USD
Spread / Average Target
+11.53%
Consensus
  1. Stock Market
  2. Equities
  3. ZTS Stock
  4. News Zoetis Inc.
  5. Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW